GenSight Biologics Announces Presentation of 72-Week Data From the REVERSE Phase III Trial of GS010 at the 45th Annual Meeting of NANOS – Business Wire

GenSight Biologics Announces Presentation of 72-Week Data From the REVERSE Phase III Trial of GS010 at the 45th Annual Meeting of NANOS  Business Wire

PARIS--(BUSINESS WIRE)--Regulatory News: “rAAV2/2-ND4 Treatment of Leber Hereditary Optic Neuropathy: 72-Week Data from the REVERSE Phase III ...